Table II.
Effect of mAbs to the Leukocyte Adhesion Molecules on Monocyte-induced Changes in HUVEC [Ca2+]i
| Monocyte treatment |
Percent inhibition | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CSLEX1 (anti-sLex) | 60.3 (anti-CD18) | HP2/1 (anti–VLA-4) | M89D3 (anti–PECAM-1) | CSLEX1 + HP2/1 | HP2/1 + M89D3 | 60.3 + HP2/1 | 60.3 + M89D3 | |||||||||
| HUVEC treatment | ||||||||||||||||
| LPS 5 h | 5.7 ± 8.4 | 1.7 ± 8.6 | 3.1 ± 5.8 | 1.8 ± 5.8 | 80.1 ± 7.1* | 0.4 ± 12.8 | 1.49 ± 3.42 | 7.9 ± 9.4 | ||||||||
| LPS 24 h | 4.3 ± 2.06 | 7.9 ± 7.4 | 81.8 ± 8.0* | 13.9 ± 12.7 | ND | ND | ND | ND | ||||||||
HUVEC monolayers were treated for 5 or 24 h with 0.5 μg/ml E. coli LPS. Monocytes were treated for 60 min in the presence or absence of mAb CSLEX1, mAb 60.3, mAb HP2/1, and mAb M89D3 (20 μg/ml). Monocytes were then added to the monolayers (monocyte/HUVEC ratio = 6–8:1) and fluorescence changes were recorded for 15 min in single Fura2-loaded HUVEC maintained in intact monolayers. Inhibitions were calculated by comparing the areas delineated by fluorescence spikes induced by mAb-treated and -untreated (control) monocytes. To make recordings comparable to each other, a maximal increase in HUVEC [Ca++]i was induced by the addition of 200 μM histamine at the end of each recording. Results are means ± SE of 3–4 independent experiments, with 10–15 replicate recordings in each experiment.
P < 0.005 (paired t test). The other results were not significantly different from control values. ND, not determined.